Patient
-
Courtesy of Merck
Half of Merck’s sales are in jeopardy. Can Keytruda’s sequel save the day?
This week’s launch of subcutaneously administered Keytruda Qlex gives Merck a safety net for the cancer drug’s daunting patent cliff.
By Michael Gibney • Oct. 2, 2025 -
Getty Images
AstraZeneca’s at-home flu vaccine is a breakthrough that could pave the way for others
FluMist Home could be a test case for at-home vaccines against a backdrop of challenging regulatory shifts.
By Alexandra Pecci • Oct. 1, 2025 -
Explore the Trendline➔
Getty Images
TrendlineArtificial intelligence & machine learning
After years of excited buzz around the potential of artificial intelligence and machine learning, pharma has begun to realize the true implications and potential value of these technologies.
By PharmaVoice staff -
Getty Images
Top pharma industry conferences in 2026
Where pharma leaders will converge, discuss and navigate the industry’s shifting landscape in 2026.
By Meagan Parrish • Oct. 1, 2025 -
Getty Images
As obesity M&A heats up, pharmas could get ‘blinded by opportunity’
With companies racing to secure GLP-1-related assets, there may be risks for moving too fast.
By Kelly Bilodeau • Sept. 29, 2025 -
Permission granted by Takeda
From atop Mt. Fuji, a Takeda team heralds a need for human plasma
The climb aimed to raise money and awareness as Takeda ramps up its plasma-derived therapy presence in Japan.
By Alexandra Pecci • Sept. 16, 2025 -
Getty Images
4 years from clinic to approval — Precigen’s ‘unprecedented’ FDA nod and what comes next
The company scored the first-ever approval to treat a potentially deadly infection leveraging its gene therapy platform.
By Meagan Parrish • Sept. 12, 2025 -
Getty Images
Ozempic for cancer? Signs point to potential benefits of GLP-1s in oncology.
Growing research suggests various ways weight loss drugs could have an impact in cancer care.
By Michael Gibney • Sept. 11, 2025 -
Getty Images
Inside pharma’s race to deliver new treatments for dwarfism
By targeting the underlying genetic mutation that drives the condition, researchers hope to increase height and address debilitating complications.
By Kelly Bilodeau • Sept. 8, 2025 -
Andrew Harnik via Getty Images
At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves
Robert F. Kennedy Jr. faced criticism Thursday even from Republican lawmakers over changes to federal vaccine policy as well as a leadership crisis at the CDC.
By Delilah Alvarado , Jonathan Gardner • Sept. 5, 2025 -
Sarah Silbiger via Getty Images
Why an FDA decision for a new drug could ripple through the ultra-rare disease space
All eyes are on Stealth BioTherapeutics as it awaits a long-delayed approval for its first-in-class treatment for Barth syndrome.
By Alexandra Pecci • Aug. 26, 2025 -
Getty Images
As gene therapies falter on the market, this biopharma is aiming to defy the odds
After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.
By Meagan Parrish • Aug. 8, 2025 -
Getty Images
Novartis’ Zolgensma sales fall again as gene therapy market woes persist
Novartis has seen sales decline in a difficult gene therapy market. Is there hope on the horizon?
By Michael Gibney • July 22, 2025 -
Getty Images
Pricing watchdog will take on the rising cost of drugs at launch
ICER’s upcoming report could shed light on how the launch price of newly approved drugs affects overall cost and access from a patient perspective.
By Michael Gibney • July 10, 2025 -
Getty Images
GLP-1 roadblocks: Discontinuation rates soar as insurers clamp down
As more drugmakers aim for the lucrative weight loss market, patient challenges linger.
By Amy Baxter • July 7, 2025 -
Getty Images
First 90 DaysA biopharma bolsters patient centricity and trial diversity goals through newly created role
Ardelyx’s newly minted chief patient officer is infusing patient experiences into every element of the business.
By Alexandra Pecci • July 1, 2025 -
Getty Images
Biogen scores Cannes Festival win with dark humored campaign
The company’s unique campaign for a rare, terminal illness nabbed millions of views and a spot on the main stage at the Cannes Lions Festival of Creativity.
By Alexandra Pecci • June 24, 2025 -
Getty Images
How a patient group tackled research diversity for one disease and triggered change for pharma
A policy win by the Foundation for Sarcoidosis Research has built momentum for other shifts that could bolster diversity in clinical trials.
By Meagan Parrish • June 17, 2025 -
Getty Images
Will pharma finally score a policy win for 340B?
The industry is awaiting guidance on a rebate approach to the contentious drug discount program for hospitals and aiming for tighter oversight.
By Kelly Bilodeau • June 16, 2025 -
Permission granted by Michael Moenning, Northlight Studio
ProfileA day in the life of GSK’s U.S. president
How Maya Martinez-Davis juggles life on the go during a busy year for new drug launches.
By Meagan Parrish • June 13, 2025 -
Getty Images
COVID vax restrictions may not hamper uptake — but the market is still under pressure
If insurers stop covering the shots and approvals become more restrictive, the most recent policy shifts could heap more challenges onto pharma’s vaccine space.
By Alexandra Pecci • June 10, 2025 -
Courtesy of AbbVie
AbbVie’s ADC win shows how pharma can break through in solid tumors
An oncology pivot recently paid off for the large pharma, which scored a milestone nod for its lead ADC.
By Meagan Parrish • May 30, 2025 -
Getty Images
Beyond the drug: Closing the knowledge gap for injectable diabetes meds
As the diabetes and weight loss market booms, more collaboration between pharma and medtech could help patients get the most out of injectable drugs.
By Michael Gibney • April 22, 2025 -
Getty Images
Genetic breakthroughs could point pharma to a long COVID drug
The discoveries also hold potential benefits for patients with other conditions, such as chronic fatigue syndrome.
By Kelly Bilodeau • April 22, 2025 -
Stephen Maturen via Getty Images
The fallout from UnitedHealth’s CEO slaying
Brian Thompson’s murder has raised questions about the cost of U.S. healthcare, embroiling insurers, drugmakers and PBMs in a battle for the future of the industry.
By PharmaVoice staff • April 15, 2025 -
Permission granted by Michelle Werner
ProfileHer son’s DMD diagnosis shook her world. As a biotech CEO, it was also an epiphany for better rare disease R&D.
Five years ago, Michelle Werner received her son’s Duchenne muscular dystrophy diagnosis with fear and desperation. Now, as CEO of Alltrna, she’s finding better ways to develop treatments.
By Michael Gibney • April 8, 2025
